Metoprolol for the Prevention of Acute Exacerbations of COPD

In this randomized trial involving patients with moderate or severe COPD, treatment with the beta-blocker metoprolol did not result in a shorter time until the first COPD exacerbation than placebo.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-12, Vol.381 (24), p.2304-2314
Hauptverfasser:	Dransfield, Mark T, Voelker, Helen, Bhatt, Surya P, Brenner, Keith, Casaburi, Richard, Come, Carolyn E, Cooper, J. Allen D, Criner, Gerard J, Curtis, Jeffrey L, Han, MeiLan K, Hatipoğlu, Umur, Helgeson, Erika S, Jain, Vipul V, Kalhan, Ravi, Kaminsky, David, Kaner, Robert, Kunisaki, Ken M, Lambert, Allison A, Lammi, Matthew R, Lindberg, Sarah, Make, Barry J, Martinez, Fernando J, McEvoy, Charlene, Panos, Ralph J, Reed, Robert M, Scanlon, Paul D, Sciurba, Frank C, Smith, Anthony, Sriram, Peruvemba S, Stringer, William W, Weingarten, Jeremy A, Wells, J. Michael, Westfall, Elizabeth, Lazarus, Stephen C, Connett, John E
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-1 Receptor Antagonists - adverse effects Adrenergic beta-1 Receptor Antagonists - therapeutic use Aged Aged, 80 and over Beta blockers Blood pressure Cardiovascular disease Chronic obstructive pulmonary disease Clinical trials Disease Progression Dyspnea Education Female Forced Expiratory Volume Heart failure Heart rate Hospitalization Hospitalization - statistics & numerical data Humans Kaplan-Meier Estimate Lung diseases Male Metoprolol Metoprolol - adverse effects Metoprolol - therapeutic use Middle Aged Mortality Obstructive lung disease Patients Prospective Studies Pulmonary Disease, Chronic Obstructive - drug therapy Quality of life Treatment Failure
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this randomized trial involving patients with moderate or severe COPD, treatment with the beta-blocker metoprolol did not result in a shorter time until the first COPD exacerbation than placebo.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1908142